These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 31235436)

  • 21. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
    Loibl S; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Dan Costa S; Gerber B; Engels K; Nekljudova V; von Minckwitz G; Untch M;
    Ann Oncol; 2017 Mar; 28(3):497-504. PubMed ID: 27831502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).
    Cottu P; Coudert B; Perol D; Doly A; Manson J; Aujoulat O; Barletta H; Chalabi N; Samelson L; Pivot X
    Eur J Cancer; 2020 Dec; 141():209-217. PubMed ID: 33176232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
    Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer.
    Delgado J; Vleminckx C; Sarac S; Sosa A; Bergh J; Giuliani R; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100074. PubMed ID: 33647599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
    Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K
    Oncology; 2019; 96(6):309-317. PubMed ID: 30893699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiotoxicity of novel HER2-targeted therapies.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
    Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA
    Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
    Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
    Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.
    Uriarte-Pinto M; Escolano-Pueyo Á; Gimeno-Ballester V; Pascual-Martínez O; Abad-Sazatornil MR; Agustín-Ferrández MJ
    Int J Clin Pharm; 2016 Apr; 38(2):446-53. PubMed ID: 26951122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
    Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
    J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S12-S16. PubMed ID: 35148934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
    Inno A; Barni S; Ghidini A; Zaniboni A; Petrelli F
    Breast Cancer Res Treat; 2019 Jan; 173(2):247-254. PubMed ID: 30317424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.